16:43 , Sep 21, 2018 |  BC Week In Review  |  Clinical News

Eureka's ET140202 leads to tumor regression in Phase I for HCC

Eureka Therapeutics Inc. (Emeryville, Calif.) said ET140202 led to one case of complete tumor regression and two cases of partial tumor regression in six evaluable patients with alpha fetoprotein (AFP)-positive hepatocellular carcinoma (HCC) in a...
15:35 , Jul 27, 2018 |  BC Week In Review  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on July 23. Sangamo expects to be the first company to...
22:49 , Jul 23, 2018 |  BC Extra  |  Company News

Sangamo acquiring TxCell, accelerates CAR Treg development

Sangamo Therapeutics Inc. (NASDAQ:SGMO) will acquire CAR Treg therapy company TxCell S.A. (Euronext:TXCL), accelerating its immunology strategy by two years, according to a presentation on Monday. Sangamo expects to be the first company to bring...
23:51 , Mar 19, 2018 |  BC Innovations  |  Translation in Brief

Crafting CAR Tregs

TxCell S.A. (Euronext:TXCL) thinks it has cracked the code on building CAR Tregs without running into the manufacturing challenges that can compromise the cells’ immunosuppressive function. The company presented data on their manufacturing process at...
04:21 , Dec 9, 2017 |  BioCentury  |  Product Development

Multimodal meeting

This year’s clinical abstracts at the American Society of Hematology meeting hint at how newer treatment modalities -- cell therapies in cancer and gene therapies in hematology -- will branch out into new indications and...
21:41 , Jul 20, 2017 |  BC Innovations  |  Product R&D

Eureka moment for TCR mimics

In the race to access the wealth of intracellular molecular targets once considered undruggable, Eureka Therapeutics Inc. is pioneering TCR-like antibodies that capitalize on the ability of TCRs to recognize tumor antigens. But the company...
18:09 , May 3, 2017 |  BC Innovations  |  Distillery Therapeutics

Cancer

INDICATION: Cancer In vitro and mouse studies suggest an antibody that binds a nine amino acid p53 fragment presented on tumor cell surfaces could help treat cancer. A mouse antibody was generated to bind the p53...
19:30 , Apr 13, 2017 |  BC Innovations  |  Translation in Brief

Presenting p53

A team from University of Oxford has described a new way to hit most mutant forms of the notoriously intractable cancer target p53 using a single therapeutic agent, and believes it could suppress growth of...
04:36 , Jan 27, 2017 |  BC Week In Review  |  Clinical News

Tedopi: Ph III Atalante 1 ongoing

An IDMC recommended continuation of the open-label, international Phase III Atalante 1 trial comparing subcutaneous Tedopi vs. IV docetaxel or IV pemetrexed in about 500 HLA-A2 positive patients. Patients will receive Tedopi every 3 weeks...
07:00 , Aug 8, 2016 |  BC Week In Review  |  Clinical News

ICT-121: Completed Phase I enrollment

ImmunoCellular completed enrollment of 20 patients with HLA-A2 positive GBM in an open-label, U.S. Phase I trial to evaluate ICT-121. Patients will receive ICI-121 once weekly for 4 weeks followed by maintenance treatment every...